<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908176</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-285-1107</org_study_id>
    <nct_id>NCT04908176</nct_id>
  </id_info>
  <brief_title>A Drug-drug Interaction Study of Avapritinib and Midazolam</brief_title>
  <official_title>A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the&#xD;
      Pharmacokinetics of Midazolam in Patients with Unresectable or Metastatic Gastrointestinal&#xD;
      Stromal Tumors (GIST)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum plasma concentration (Cmax) of midazolam</measure>
    <time_frame>Day 1 and Day 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time of maximum plasma concentration (tmax) of midazolam</measure>
    <time_frame>Day 1 and Day 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration-time curve (AUC) of midazolam</measure>
    <time_frame>Day 1 and Day 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AEs), serious AEs (SAEs),</measure>
    <time_frame>up to approximately 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax at steady state (Cmax, ss) of avapritinib</measure>
    <time_frame>Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax at steady state (Cmax, ss) of metabolite</measure>
    <time_frame>Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the plasma concentration-time curve at steady state (AUC,ss) of avapritinib</measure>
    <time_frame>Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the plasma concentration-time curve at steady state (AUC,ss) of metabolite</measure>
    <time_frame>Day 18</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <condition>GIST</condition>
  <arm_group>
    <arm_group_label>Patients with metastatic, unresectable GIST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 5 mg of midazolam orally on Day 1 and Day 18. Patients will receive avapritinib 300 mg, orally on Day 3 through Day 19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avapritinib</intervention_name>
    <description>avapritinib tablets</description>
    <arm_group_label>Patients with metastatic, unresectable GIST</arm_group_label>
    <other_name>BLU-285</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>midazolam syrup</description>
    <arm_group_label>Patients with metastatic, unresectable GIST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be ≥18 years of age at the time of signing the informed consent&#xD;
&#xD;
          2. Must have histologically confirmed metastatic or unresectable GIST that has recurred&#xD;
             or progressed after at least 4 lines of prior systemic SOC therapy or the Investigator&#xD;
             has determined that treatment with SOC therapy is not appropriate for patients who&#xD;
             failed at least 2 lines of prior SOC&#xD;
&#xD;
          3. Patient's tumor must have known KIT mutation&#xD;
&#xD;
          4. Must be able to swallow an oral medication&#xD;
&#xD;
          5. Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          6. Patient agrees to use contraception consistent with local regulations&#xD;
&#xD;
          7. Must provide signed informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient's tumor has known PDGFRA mutation&#xD;
&#xD;
          2. Known hypersensitivity to avapritinib, midazolam, or any of their excipients&#xD;
&#xD;
          3. Have received previous therapy with avapritinib&#xD;
&#xD;
          4. Have any of the following laboratory abnormalities before the first dose of study&#xD;
             drug:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &gt;3 × upper&#xD;
                  limit of normal (ULN) if no hepatic metastases are present; &gt;5 × ULN if hepatic&#xD;
                  metastases are present&#xD;
&#xD;
               -  Total bilirubin &gt;1.5 × ULN; &gt;3 × ULN in the presence of Gilbert's Disease&#xD;
&#xD;
               -  Estimated (Cockcroft-Gault formula) or measured creatinine clearance &lt;60 mL/min&#xD;
&#xD;
               -  Platelet count &lt;90 × 109/L&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt;1.0 × 109/L&#xD;
&#xD;
               -  Hemoglobin &lt;9 g/dL. Transfusion and erythropoietin may be used to reach at least&#xD;
                  9 g/dL but must have been administered at least 2 weeks before the first dose of&#xD;
                  the study drug.&#xD;
&#xD;
          5. Require therapy with a concomitant medication that is a strong and moderate CYP3A4&#xD;
             inhibitors or inducers&#xD;
&#xD;
          6. Consumption of any nutrients known to modulate CYP3A4 enzymes activity (eg, grapefruit&#xD;
             or grapefruit juice, pomelo juice, star fruit, or Seville [blood] orange and&#xD;
             derivative products, cruciferous vegetables [eg, broccoli, cauliflower, cabbage,&#xD;
             brussel sprouts]) within 14 days before screening and during the study until the end&#xD;
             of the Main Treatment Period&#xD;
&#xD;
          7. Have received a prior anticancer drug less than 5 half-lives or 14 days (whichever is&#xD;
             shorter) before screening&#xD;
&#xD;
          8. Have had a major surgical procedure within 14 days of the first dose of study drug or&#xD;
             have significant traumatic injury within 28 days before screening&#xD;
&#xD;
          9. Have history of a seizure disorder (eg, epilepsy) or requirement for anticonvulsant&#xD;
             medications&#xD;
&#xD;
         10. Have history of a cerebrovascular accident or transient ischemic attacks within 1 year&#xD;
             before screening&#xD;
&#xD;
         11. Have known risk of intracranial bleeding, such as a brain aneurysm or history of&#xD;
             subdural or subarachnoid bleeding&#xD;
&#xD;
         12. Have primary brain malignancy or metastases to the brain&#xD;
&#xD;
         13. Have corrected QT interval using Fridericia's formula (QTcF) &gt;450 msec&#xD;
&#xD;
         14. Have clinically significant, uncontrolled, cardiovascular disease, including&#xD;
             congestive heart failure Grades 2, 3, or 4 according to the New York Heart Association&#xD;
             classification, myocardial infarction, or unstable angina within the previous 6&#xD;
             months, or uncontrolled hypertension&#xD;
&#xD;
         15. Have experienced any hemorrhage or bleeding event National Cancer Institute Common&#xD;
             Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade ≥3 within 4&#xD;
             weeks before screening&#xD;
&#xD;
         16. Patients who have a symptomatic nonhealing wound, ulcer, GI perforation, or bone&#xD;
             fracture&#xD;
&#xD;
         17. Have received organ or allogenic bone marrow or peripheral blood stem cell transplant&#xD;
&#xD;
         18. Have known diagnosis of human immunodeficiency virus infection or active viral&#xD;
             hepatitis; viral testing is not required&#xD;
&#xD;
         19. History of alcohol consumption exceeding 2 standard drinks per day on average (1&#xD;
             standard drink = 14 grams of alcohol). Alcohol consumption will be prohibited 48 hours&#xD;
             before screening and throughout the entire the Main Treatment Period&#xD;
&#xD;
         20. Use of tobacco- or nicotine-containing products within 3 months of enrollment&#xD;
&#xD;
         21. Is a female patient who is unwilling, if not postmenopausal or surgically sterile, to&#xD;
             abstain from sexual intercourse or employ highly effective contraception from the time&#xD;
             of informed consent and for until at least 6 months after the last dose of study drug.&#xD;
             Males who are unwilling, if not surgically sterile, to abstain from sexual intercourse&#xD;
             or employ highly effective contraception from the time of informed consent and for at&#xD;
             least 90 days after the last dose of study drug.&#xD;
&#xD;
         22. Is a female patient who is pregnant, as documented by a serum beta human chorionic&#xD;
             gonadotropin (β-hCG) pregnancy test consistent with pregnancy obtained within 7 days&#xD;
             before the first dose of study drug. Patients with β-hCG values that are within the&#xD;
             range for pregnancy but are not pregnant (false positives) may be enrolled with&#xD;
             written consent of the Sponsor after pregnancy has been ruled out. Females of&#xD;
             nonchildbearing potential (postmenopausal for more than 12 months, bilateral tubal&#xD;
             ligation, bilateral oophorectomy, or hysterectomy) do not require a serum β-hCG test.&#xD;
&#xD;
         23. Female who is breastfeeding&#xD;
&#xD;
         24. Have a prior or ongoing clinically significant illness, medical condition, surgical&#xD;
             history, physical finding, or laboratory abnormality that, in the Investigator's&#xD;
             opinion, could affect the safety of the patient, alter the absorption, distribution,&#xD;
             metabolism or excretion of the study drugs, or impair the assessment of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Blueprint Medicines</last_name>
    <phone>617-714-6707</phone>
    <email>medinfo@blueprintmedicines.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

